Re: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Open Access
Publisher Website
Google Scholar
Abstract
Despite admonitions that physicians should discuss current information on tamoxifen with their patients, the preponderance of scientific primary and secondary reports and commentaries focus on relative risk information. While current trial results do not answer several important questions and while our individual risk assessment tools are less than ideal, we can lay out absolute risk and benefit data.

This publication has 3 references indexed in Scilit: